Comparison of single and divided daily dose spironolactone in the control of hypertension.
作者信息
Bell G M, Fananapazir L, Anderton J L
出版信息
Br J Clin Pharmacol. 1981 Oct;12(4):585-8. doi: 10.1111/j.1365-2125.1981.tb01271.x.
Abstract
摘要
相似文献
1
Comparison of single and divided daily dose spironolactone in the control of hypertension.单剂量与分剂量螺内酯控制高血压的比较。
Br J Clin Pharmacol. 1981 Oct;12(4):585-8. doi: 10.1111/j.1365-2125.1981.tb01271.x.
2
Antagonism of fludrocortisone by spironolactone and canrenone.螺内酯和坎利酮对氟氢可的松的拮抗作用。
Br J Clin Pharmacol. 1976 Feb;3(1):201-4. doi: 10.1111/j.1365-2125.1976.tb00593.x.
3
Effect of spironolactone and its main metabolite canrenone on the renin-angiotensin-aldosterone-system during long-term treatment in rats.
Acta Endocrinol (Copenh). 1979 Jan;90(1):147-56. doi: 10.1530/acta.0.0900147.
4
5
A comparison of some extra-renal effects of spironolactone and canrenone.螺内酯和坎利酮的一些肾外效应比较。
Br J Clin Pharmacol. 1979 Apr;7(4):385-92. doi: 10.1111/j.1365-2125.1979.tb00950.x.
6
Validation of plasma and urinary canrenone for determination of bioavailability of spironolactone--comparison of tablets with solution/suspension.验证血浆和尿中坎利酮用于测定螺内酯生物利用度——片剂与溶液/混悬液的比较
Int J Clin Pharmacol Biopharm. 1977 May;15(5):205-10.
7
Canrenone and androgen receptor-active materials in plasma of cirrhotic patients during long-term K-canrenoate or spironolactone therapy.长期使用钾坎利酸钾或螺内酯治疗的肝硬化患者血浆中的坎利酮及雄激素受体活性物质
Digestion. 1989;44(3):155-62. doi: 10.1159/000199905.
8
Spirolactones: clinical and pharmacologic studies.螺内酯：临床与药理学研究
Adv Nephrol Necker Hosp. 1977;7:199-215.
9
Spironolactone and potassium canrenoate in normal man.正常人中的螺内酯和坎利酸钾。
Clin Pharmacol Ther. 1976 Aug;20(2):167-77. doi: 10.1002/cpt1976202167.
10
Determination of canrenone, the major metabolite of spironolactone, in plasma and urine by high-performance liquid chromatography.采用高效液相色谱法测定血浆和尿液中螺内酯的主要代谢物坎利酮。
J Chromatogr. 1983 Oct 14;277:191-9. doi: 10.1016/s0378-4347(00)84836-7.
引用本文的文献
1
Eplerenone Versus Spironolactone in Resistant Hypertension: an Efficacy and/or Cost or Just a Men's Issue?依普利酮对比螺内酯治疗抵抗性高血压：疗效和/或成本，还是仅仅是男性问题？
Curr Hypertens Rep. 2019 Mar 2;21(3):22. doi: 10.1007/s11906-019-0924-0.
2
What is the role of aldosterone excess in resistant hypertension and how should it be investigated and treated?醛固酮增多在难治性高血压中的作用是什么，应该如何进行检查和治疗？
Curr Cardiol Rep. 2011 Dec;13(6):520-6. doi: 10.1007/s11886-011-0224-z.
3
Treatment considerations with aldosterone receptor antagonists.醛固酮受体拮抗剂的治疗考量
J Clin Hypertens (Greenwich). 2011 Jan;13(1):65-9. doi: 10.1111/j.1751-7176.2010.00377.x. Epub 2010 Oct 4.
本文引用的文献
1
RELATIONSHIP OF PLASMA ALDADIENE LEVELS AND ANTIMINERALOCORTICOID EFFECTS OF SPIRONOLACTONE IN THE LABORATORY.实验室中血浆醛二烯水平与螺内酯抗盐皮质激素作用的关系。
Proc Soc Exp Biol Med. 1964 Mar;115:837-40. doi: 10.3181/00379727-115-29052.
2
A fluorimetric method for the determination of a major spironolactone (Aldactone) metabolite in human plasma.一种用于测定人血浆中主要螺内酯（安体舒通）代谢物的荧光测定法。
J Pharmacol Exp Ther. 1962 Mar;135:312-6.
3
Comparison of a single-dose and twice-a-day spironolactone therapy in mild hypertension.单剂量与每日两次螺内酯治疗轻度高血压的比较。
Med J Aust. 1980 Feb 9;1(3):124-5. doi: 10.5694/j.1326-5377.1980.tb134686.x.
4
Spironolactone. III. Canrenone--maximum and minimum steady-state plasma levels.螺内酯。III. 坎利酮——最大和最小稳态血浆水平。
Clin Pharmacol Ther. 1976 Feb;19(2):177-82. doi: 10.1002/cpt1976192177.
5
Spironolactone. I. Disposition and metabolism.
Clin Pharmacol Ther. 1976 Feb;19(2):158-69. doi: 10.1002/cpt1976192158.
6
Spironolactone and canrenoate-K: relative potency at steady state.螺内酯和坎利酸钾：稳态时的相对效价。
Clin Pharmacol Ther. 1977 May;21(5):602-9. doi: 10.1002/cpt1977215602.
7
Antihypertensive responses to spironolactone in normal renin hypertension.正常肾素性高血压患者对螺内酯的降压反应
Clin Pharmacol Ther. 1978 Nov;24(5):525-30. doi: 10.1002/cpt1978245525.
8
Spironolactone.螺内酯
Am Heart J. 1978 Sep;96(3):389-400. doi: 10.1016/0002-8703(78)90052-2.
Zotero 插件